Ipamorelin
Ipamorelin has been in phase II clinical trials for the treatment of postoperative ileus and gastrointestinal dysmotility. However, no recent development has been reported.
The compound was discovered by Novo Nordisk, and in 2006 licensed to Sapphire Therapeutics (acquired by Helsinn Therapeutics in 2009).
General Information
Update Date：2016-01-19
- Drug Name：
- Ipamorelin
- Research Code：
- NNC-26-0161
- Trade Name：
- MOA：
- Growth hormone secretagogues receptor agonists
- Indication：
- Postoperative ileus; Gastrointestinal motility disorders
- Status：
- Phase II (Pending)
- Company：
- Novo Nordisk (Originator) , Helsinn
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-19
|
Molecular Weight | 711.85 | ||||||||||||
| Formula | C38H49N9O5 | |||||||||||||
| CAS No. | 170851-70-4 (Ipamorelin); | |||||||||||||
| Chemical Name | L-Lysinamide, 2-methylalanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl- | |||||||||||||
| Ipamorelin （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||